Publications

BibTex format

@article{Vallejo-Vaz:2023:10.1007/s10557-022-07343-x,
author = {Vallejo-Vaz, AJ and Bray, S and Villa, G and Brandts, J and Kiru, G and Murphy, J and Banach, M and De, Servi S and Gaita, D and Gouni-Berthold, I and Hovingh, GK and Jozwiak, JJ and Jukema, JW and Kiss, RG and Kownator, S and Iversen, HK and Maher, V and Masana, L and Parkhomenko, A and Peeters, A and Clifford, P and Raslova, K and Siostrzonek, P and Romeo, S and Tousoulis, D and Vlachopoulos, C and Vrablik, M and Catapano, AL and Poulter, NR and Ray, KK},
doi = {10.1007/s10557-022-07343-x},
journal = {Cardiovascular Drugs and Therapy},
pages = {941--953},
title = {Implications of ACC/AHA Versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI},
url = {http://dx.doi.org/10.1007/s10557-022-07343-x},
volume = {37},
year = {2023}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PurposeLow-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (< 70 vs. < 55 mg/dl, respectively). In the DA VINCI study, residual cardiovascular risk was predicted in ASCVD patients. The extent to which relative and absolute risk might be lowered by achieving ACC/AHA versus ESC/EAS LDL-C recommended approaches was simulated.MethodsDA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of < 70 or < 55 mg/dl (LDL-C of 69 or 54 mg/dl, respectively) was calculated. Relative and absolute risk reductions (RRRs and ARRs) were simulated.ResultsOf the 2039 patients, 61% did not achieve LDL-C < 70 mg/dl. For patients with LDL-C ≥ 70 mg/dl, median (interquartile range) baseline LDL-C and 10-year CVR were 93 (81–115) mg/dl and 32% (25–43%), respectively. Median LDL-C reductions of 24 (12–46) and 39 (27–91) mg/dl were needed to achieve an LDL-C of 69 and 54 mg/dl, respectively. Attaining ACC/AHA or ESC/EAS goals resulted in simulated RRRs of 14% (7–25%) and 22% (15–32%), respectively, and ARRs of 4% (2–7%) and 6% (4–9%), respectively.ConclusionIn ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.
AU  - Vallejo-Vaz,AJ
AU  - Bray,S
AU  - Villa,G
AU  - Brandts,J
AU  - Kiru,G
AU  - Murphy,J
AU  - Banach,M
AU  - De,Servi S
AU  - Gaita,D
AU  - Gouni-Berthold,I
AU  - Hovingh,GK
AU  - Jozwiak,JJ
AU  - Jukema,JW
AU  - Kiss,RG
AU  - Kownator,S
AU  - Iversen,HK
AU  - Maher,V
AU  - Masana,L
AU  - Parkhomenko,A
AU  - Peeters,A
AU  - Clifford,P
AU  - Raslova,K
AU  - Siostrzonek,P
AU  - Romeo,S
AU  - Tousoulis,D
AU  - Vlachopoulos,C
AU  - Vrablik,M
AU  - Catapano,AL
AU  - Poulter,NR
AU  - Ray,KK
DO  - 10.1007/s10557-022-07343-x
EP  - 953
PY  - 2023///
SN  - 0920-3206
SP  - 941
TI  - Implications of ACC/AHA Versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI
T2  - Cardiovascular Drugs and Therapy
UR  - http://dx.doi.org/10.1007/s10557-022-07343-x
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000795634000002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://link.springer.com/article/10.1007/s10557-022-07343-x
UR  - http://hdl.handle.net/10044/1/97688
VL  - 37
ER  -

Download

Professor Neil Poulter

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)